Efficacy and Safety of Oral Small Molecule Glucagon-Like Peptide 1 Receptor Agonist Danuglipron for Glycemic Control Among Patients With Type 2 Diabetes

A Small-Molecule Oral Agonist of the Human Glucagon-like Peptide-1 Receptor

(2022) David A. Griffith et al.   JOURNAL OF MEDICINAL CHEMISTRY

Danuglipron (PF-06882961) in type 2 diabetes: a randomized, placebo-controlled, multiple ascending-dose phase 1 trial

(2021) Aditi R. Saxena et al.   NATURE MEDICINE

Effect of Various Dosing Conditions on the Pharmacokinetics of Oral Semaglutide, a Human Glucagon-Like Peptide-1 Analogue in a Tablet Formulation

(2021) Tine A. Bækdal et al.   Diabetes Therapy

9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2022

(2021)   DIABETES CARE

Clinical review of the efficacy and safety of oral semaglutide in patients with type 2 diabetes compared with other oral antihyperglycemic agents and placebo

(2020) Frank Lavernia et al.   POSTGRADUATE MEDICINE

2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

(2019) John B. Buse et al.   DIABETES CARE

Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1

(2018) Daniel J. Drucker   Cell Metabolism

6. Glycemic Targets: Standards of Medical Care in Diabetes—2019

(2018)   DIABETES CARE

Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabetes

(2017) Melanie Davies et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Discovery, characterization, and clinical development of the glucagon-like peptides

(2017) Daniel J. Drucker et al.   JOURNAL OF CLINICAL INVESTIGATION

A Phase 2, Randomized, Dose-Finding Study of the Novel Once-Weekly Human GLP-1 Analog, Semaglutide, Compared With Placebo and Open-Label Liraglutide in Patients With Type 2 Diabetes

(2015) Michael A. Nauck et al.   DIABETES CARE

Dose-finding results in an adaptive, seamless, randomized trial of once-weekly dulaglutide combined with metformin in type 2 diabetes patients (AWARD-5)

(2014) Z. Skrivanek et al.   DIABETES OBESITY & METABOLISM

World Medical Association Declaration of Helsinki

(2013)   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Persistence with injectable antidiabetic agents in members with type 2 diabetes in a commercial managed care organization

(2009) Catherine E. Cooke et al.   CURRENT MEDICAL RESEARCH AND OPINION